AIDS Prevention

Bioption, IAVI partnering to develop globally accessible AIDS vaccines

Published in AIDS Weekly, June 3rd, 2002

Swedish biotechnology firm Bioption AB is partnering with the International AIDS Vaccine Initiative (IAVI) to develop and test a new approach for vaccines that can train the immune system to protect against HIV/AIDS.

The vaccines are being built from a technology, Semliki Forest virus (SFV) alphavirus replicons, pioneered by scientists at the Karolinska Institute in Sweden.

The nonprofit IAVI is financing and coordinating the research, with the goal of starting human testing of SFV-based AIDS vaccines within 2 years. Bioption and IAVI have agreed to use their joint ownership of any successful AIDS vaccines to provide them to developing countries...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2002-06-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry